Summary
Biocon has done a "Aurobindo" & "Dr. Reddy's" with Mylan. In all my news articles I mentioned watch out for more of such deals. I never anticipated the speed at which it is happening!!!
Analysis
The Business of pharmaceuticals is going through sea change currently.
Cost effective generics / biosimilars are the flavor of the industry currently.
facing challenging situations from governments, insurance agencies etc... the pharma companies have been forced to rationalize product cost.
Biosimilars have so far been an unexploited territory, in the cost effective medication segment.
Mylan sensing the long term opportunity here along with synergies with its core business of Generics have pulled a good deal for them selves and their India partner.
This author consults with leading institutions through GLG
Analyses are solely the work of the authors and have not been edited or endorsed by GLG.
